<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02928523</url>
  </required_header>
  <id_info>
    <org_study_id>MPOH02</org_study_id>
    <nct_id>NCT02928523</nct_id>
  </id_info>
  <brief_title>PreventiOn of DYSbioSis Complications With Autologous FMT in AML Patients</brief_title>
  <acronym>ODYSSEE</acronym>
  <official_title>PreventiOn of DYSbioSis Complications With Autologous Fecal Microbiota Transplantation in acutE myEloid Leukemia Patients Undergoing Intensive Treatment: A Feasibility and Safety Study ODYSSEE STUDY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MaaT Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MaaT Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose to use autologous fecal microbiota transplantation (AFMT) to acute&#xD;
      myeloid leukemia (AML) patients treated with intensive chemotherapy and antibiotics in order&#xD;
      to restore the balance of their intestinal microbiome and thereby eradicate treatment-induced&#xD;
      multidrug resistant bacteria (MDRB), infection-related complications, as well as sequelae to&#xD;
      the gastrointestinal tract. Therefore, the investigators propose to perform a single-arm&#xD;
      multicentre prospective fecal microbiota transplantation (FMT) trial in AML patients&#xD;
      receiving intensive chemotherapy, and who are usually heavily treated with broad-spectrum&#xD;
      antibiotics during aplasia that generate a profound status of dysbiosis. For this purpose, at&#xD;
      the time of admission and AML diagnosis, patients will be requested to donate stools that&#xD;
      will be comprehensively screened, and if deemed appropriate according to protocol criteria,&#xD;
      conditioned and stored frozen until future processing and transplantation after aplasia&#xD;
      completion.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Actual">June 20, 2018</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of AFMT efficacy in dysbiosis correction by measure of microbiota diversity</measure>
    <time_frame>40 days</time_frame>
    <description>Comparison of Alpha and Beta diversity indexes at baseline, after chemotherapy and after AFMT will be performed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of AFMT efficacy in MDRB eradication based on bacterial culture</measure>
    <time_frame>40 days</time_frame>
    <description>MDRB carriage and resistome will be compared at baseline, after chemotherapy and after AFMT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Definition of a dysbiosis biosignature using combination of biological parameters</measure>
    <time_frame>40 days</time_frame>
    <description>Microbiota sequencing results will be correlated with immune parameters</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Leukemia, Myeloid, Acute</condition>
  <arm_group>
    <arm_group_label>Autologous Fecal Microbiota Transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive autologous fecal microbiota transplantation (MaaT011- 150 mL rectal enema) - 2 administrations 24 hours apart.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Autologous Fecal Microbiota Transplantation</intervention_name>
    <arm_group_label>Autologous Fecal Microbiota Transplantation</arm_group_label>
    <other_name>MaaT011</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients ≥ 18 and ≤ 75 years old with de novo diagnosis of AML or high-risk&#xD;
             myelodysplastic syndrom for whom intensive induction chemotherapy is anticipated&#xD;
             within 10 days after admission&#xD;
&#xD;
          -  Patients willing to donate stool samples and to follow protocol recommendations&#xD;
&#xD;
          -  Signature of informed and written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute promyelocytic leukemia (AML-M3)&#xD;
&#xD;
          -  Known allergy or intolerance to trehalose or maltodextrin&#xD;
&#xD;
          -  Pregnancy: positive urinary or blood test in female of childbearing potential&#xD;
&#xD;
          -  Severe disease with a life expectancy &lt; 3 months&#xD;
&#xD;
          -  Other ongoing interventional protocol that might interfere with the study&#xD;
&#xD;
          -  Non eligibility for collection of autologous stools upon admission:&#xD;
&#xD;
               -  Patients refusing to consent&#xD;
&#xD;
               -  Antibiotherapy at the time of study inclusion ≥ 4 days&#xD;
&#xD;
               -  Concomitant or previous diagnosis of a significant inflammatory bowel disease&#xD;
                  (UC, CD) or other progressive digestive disease requesting treatment or further&#xD;
                  medical exploration&#xD;
&#xD;
               -  Presence of severe colitis of any etiology at the time of admission or severe&#xD;
                  digestive disorders (acute or chronic diarrhea) within 3 months preceding&#xD;
                  inclusion&#xD;
&#xD;
               -  Patient getting a recent colonoscopy (within 3 months preceding inclusion)&#xD;
&#xD;
          -  Detection of MDRB, pathogenic bacteria, parasites, norovirus and/or rotavirus during&#xD;
             screening of autologous stool collected at baseline&#xD;
&#xD;
          -  Non eligibility for inoculum transplantation: persistent mucositis, colitis, or&#xD;
             haemorrhoids, presence of blood in more than 50% of patient's faeces the week&#xD;
             preceding the transplantation&#xD;
&#xD;
          -  Non feasibility of inoculum procedure: patient refusal; technical or biological&#xD;
             mismatch of the inoculum&#xD;
&#xD;
          -  Absence of effective contraceptive method for female of childbearing potential&#xD;
&#xD;
          -  Lactation&#xD;
&#xD;
          -  Inability to give an informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamad Mohty, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>APHP</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IPC</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HCL Lyon Sud</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>May 26, 2016</study_first_submitted>
  <study_first_submitted_qc>October 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2016</study_first_posted>
  <last_update_submitted>September 4, 2020</last_update_submitted>
  <last_update_submitted_qc>September 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Autologous Fecal Microbiota Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Dysbiosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

